Read More 3 minute read Uncategorized Why Tuesday Morning Shares Are Trading Lower By 38%; Here Are 31 Stocks Moving Premarket By Lisa Levin Today, 3:52 AM Gainers Neptune Wellness Solutions Inc. (NASDAQ: NEPT) shares rose 106.9% to $0.5482 in pre-market trading on heavy volume.
Read More 2 minute read Uncategorized 12 Health Care Stocks Moving In Monday’s Intraday Session By Benzinga Insights Today, 3:52 AM Gainers Scopus BioPharma (NASDAQ:SCPS) stock rose 50.0% to $0.12 during Monday’s regular session. The current volume of 120.0K…
Read More 21 minute read Uncategorized Earnings Scheduled For November 8, 2022 By Benzinga Insights Today, 3:52 AM Companies Reporting Before The Bell • Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Read More 25 minute read Uncategorized Stocks That Hit 52-Week Lows On Friday By Benzinga Insights Today, 3:52 AM On Friday morning, 446 companies hit new 52-week lows.
Read More 12 minute read Uncategorized Stocks That Hit 52-Week Lows On Wednesday By Benzinga Insights Today, 3:52 AM On Wednesday, 200 companies hit new 52-week lows.
Read More 47 minute read Uncategorized Stocks That Hit 52-Week Lows On Tuesday By Benzinga Insights Today, 3:52 AM On Tuesday, 838 companies hit new 52-week lows.
Read More 28 minute read Uncategorized Stocks That Hit 52-Week Lows On Monday By Benzinga Insights Today, 3:52 AM During Monday's trading, 528 companies set new 52-week lows.
Read More 2 minute read Uncategorized 12 Health Care Stocks Moving In Friday’s After-Market Session By Benzinga Insights Today, 3:52 AM Gainers
Read More 1 minute read Uncategorized HC Wainwright & Co. Maintains Buy on Aptinyx, Lowers Price Target to $1 By Benzinga Newsdesk Today, 3:52 AM HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aptinyx (NASDAQ:APTX) with a Buy and lowers the price target from $2 to $1.
Read More 2 minute read Uncategorized Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary By Ragothaman Srinivasan Today, 3:52 AM Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…